Quantcast

Galil Medical Announces Medical University of South Carolina Medical Center Enrolls First Patient in Renal Trace Registry

November 19, 2010

Galil Medical’s TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy.

Arden Hills, MN (PRWEB) November 18, 2010

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Medical University of South Carolina enrolled their first TRACE Registry patient.

The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy treatment for patients with renal masses. Cryotherapy is a minimally invasive procedure using small cryoablation needles to target and freeze tumors and other suspicious masses.

“Although my colleagues and I have been performing renal cryotherapy since it emerged as an exciting technology over 10 years ago, we continually look at ways to improve its delivery to patients,” said Dr. Stephen Savage, MUSC Professor of Urology. Dr. Savage is an expert in kidney cancer and currently performs laparoscopic kidney cryotherapy. He is also the Director of Minimally Invasive Urology at MUSC. “We have been active in evaluating its efficacy and applications as an institution with expertise in the area, as evidenced by our publications. TRACE provides an opportunity for us to move further in working with a select few colleagues across the country who have similar expertise in this technique. We see it as another valuable opportunity to serve the residents of South Carolina.”

Standard treatment options for renal cell cancer include total and partial nephrectomies, open and laparoscopic procedures. Minimally invasive ablative therapies are increasingly accepted treatment options due to favorable clinical outcomes, reduced procedural pain, nephron sparing techniques, fewer complications and faster patient recovery.

Galil Medical initiated the TRACE Registry in May 2010 and expects to enroll an estimated 250 patients across approximately ten sites in the United States, including MUSC. Martin J. Emerson, President and CEO of Galil Medical commented, “Through the TRACE Registry we are fulfilling our commitment of developing robust clinical data.”    

About Galil Medical Galil Medical is a global leader in delivering innovative cryotherapy solutions. The company is addressing patient conditions across multiple physician specialties; treatment areas include conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain applications. Company offices are in Arden Hills, Minnesota; Yokneam, Israel; and London, United Kingdom. Shareholders include Thomas, McNerney & Partners, The Vertical Group, and Investor Growth Capital.

Contact information:

Martin J. Emerson

President and CEO, Galil Medical

Tel: +1 651 287 5050

Email: marty(dot)emerson(at)galilmedical(dot)com

Bill Jacqmein

Chief Technology Officer

Tel: +1 651 287 5090

Email: Bill(dot)Jacqmein(at)galilmedical(dot)com

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2010/11/prweb4806434.htm


Source: prweb



comments powered by Disqus